336 related articles for article (PubMed ID: 14522889)
1. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
2. Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
[TBL] [Abstract][Full Text] [Related]
3. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
[TBL] [Abstract][Full Text] [Related]
4. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA
Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660
[TBL] [Abstract][Full Text] [Related]
5. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.
Edmunds SC; Cree IA; Dí Nícolantonío F; Hungerford JL; Hurren JS; Kelsell DP
Br J Cancer; 2003 May; 88(9):1403-5. PubMed ID: 12778069
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutations in conjunctival melanoma.
Gear H; Williams H; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
8. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
Yazdi AS; Ghoreschi K; Sander CA; Röcken M
Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
[TBL] [Abstract][Full Text] [Related]
9. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.
Gorden A; Osman I; Gai W; He D; Huang W; Davidson A; Houghton AN; Busam K; Polsky D
Cancer Res; 2003 Jul; 63(14):3955-7. PubMed ID: 12873990
[TBL] [Abstract][Full Text] [Related]
10. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
[TBL] [Abstract][Full Text] [Related]
11. The T1799A point mutation is present in posterior uveal melanoma.
Janssen CS; Sibbett R; Henriquez FL; McKay IC; Kemp EG; Roberts F
Br J Cancer; 2008 Nov; 99(10):1673-7. PubMed ID: 18985043
[TBL] [Abstract][Full Text] [Related]
12. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
[TBL] [Abstract][Full Text] [Related]
14. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea.
Weber A; Hengge UR; Urbanik D; Markwart A; Mirmohammadsaegh A; Reichel MB; Wittekind C; Wiedemann P; Tannapfel A
Lab Invest; 2003 Dec; 83(12):1771-6. PubMed ID: 14691295
[TBL] [Abstract][Full Text] [Related]
15. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
16. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
17. Absence of V599E BRAF mutations in desmoplastic melanomas.
Davison JM; Rosenbaum E; Barrett TL; Goldenberg D; Hoque MO; Sidransky D; Westra WH
Cancer; 2005 Feb; 103(4):788-92. PubMed ID: 15641040
[TBL] [Abstract][Full Text] [Related]
18. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
[TBL] [Abstract][Full Text] [Related]
19. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
[TBL] [Abstract][Full Text] [Related]
20. Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Deichmann M; Thome M; Benner A; Kirschner M; Hassanzadeh J; Kurzen H
BMC Cancer; 2005 Jun; 5():58. PubMed ID: 15935100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]